APA

Kater A. P., Kersting S., van Norden Y., Dubois J., Dobber J. A., Mellink C. H., Evers L. M., Croon-de Boer F., Schreurs J., van der Spek E., Visser H., Idink C., Wittebol S., Hoogendoorn M., Tonino S. H., Mobasher M. & Levin M. (20190923). Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. : Blood advances.

Chicago

Kater Arnon P, Kersting Sabina, van Norden Yvette, Dubois Julie, Dobber Johan A, Mellink Clemens H, Evers Ludo M, Croon-de Boer Fransien, Schreurs John, van der Spek Ellen, Visser Hein, Idink Cecile, Wittebol Shulamiet, Hoogendoorn Mels, Tonino Sanne H, Mobasher Mehrdad and Levin Mark-David. 20190923. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. : Blood advances.

Harvard

Kater A. P., Kersting S., van Norden Y., Dubois J., Dobber J. A., Mellink C. H., Evers L. M., Croon-de Boer F., Schreurs J., van der Spek E., Visser H., Idink C., Wittebol S., Hoogendoorn M., Tonino S. H., Mobasher M. and Levin M. (20190923). Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. : Blood advances.

MLA

Kater Arnon P, Kersting Sabina, van Norden Yvette, Dubois Julie, Dobber Johan A, Mellink Clemens H, Evers Ludo M, Croon-de Boer Fransien, Schreurs John, van der Spek Ellen, Visser Hein, Idink Cecile, Wittebol Shulamiet, Hoogendoorn Mels, Tonino Sanne H, Mobasher Mehrdad and Levin Mark-David. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. : Blood advances. 20190923.